523 filings
8-K
IOVA
Iovance Biotherapeutics Inc
23 May 24
Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting
8:00pm
DEFA14A
IOVA
Iovance Biotherapeutics Inc
17 May 24
Additional proxy soliciting materials
5:15pm
10-Q
2024 Q1
IOVA
Iovance Biotherapeutics Inc
Quarterly report
9 May 24
5:10pm
8-K
IOVA
Iovance Biotherapeutics Inc
9 May 24
Iovance Biotherapeutics Reports First Quarter 2024
4:06pm
ARS
2023 FY
IOVA
Iovance Biotherapeutics Inc
1 May 24
Annual report to shareholders
5:05pm
DEFA14A
u3qr9ze c28qe6
29 Apr 24
Additional proxy soliciting materials
5:07pm
8-K
q2joyjxvgjc5mkv6wla
3 Apr 24
Other Events
5:15pm
8-K
3uv2 5heo0q
29 Mar 24
Departure of Directors or Certain Officers
5:00pm
8-K
75ww1 ym3je
4 Mar 24
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
8:00am
8-K
cmypy729oqs6i
29 Feb 24
Other Events
7:30am
8-K
kuj4ave pi3n1oiwj6
28 Feb 24
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023
4:05pm
8-K
0xx9q8v
22 Feb 24
Other Events
4:53pm
424B5
y5sg2y7nqr7xvkl9jlhd
21 Feb 24
Prospectus supplement for primary offering
4:44pm
8-K
2evpe1wh7cq
20 Feb 24
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
5:23pm
8-K
ujg40s
20 Feb 24
Iovance’s AMTAGVITM (lifileucel) Receives U.S. FDA Accelerated Approval
6:03am
8-K
hh0ol04w0
26 Jan 24
Other Events
12:00am
8-K
36omtd69
8 Jan 24
Other Events
5:03pm
8-K
z1c75goog4zdpy5zr0
27 Dec 23
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
5:00pm